Caristo to Unveil New Clinical and Research Results at SCCT 2025

Data from the large-scale implementation of CaRi-Heart technology in five National Health Service (NHS) hospitals in the UK will reveal the technology's impact on tailoring patient management with inflammation-driven risk stratification. Latest clinical results from this real-world implementation will be presented and discussed on July 19 at 7:00am at the Caristo symposium(SCCT congress venue room 512 C/F), featuring: Data from the large-scale implementation of CaRi-Heart technology in five...

Data from the large-scale implementation of CaRi-Heart technology in five National Health Service (NHS) hospitals in the UK will reveal the technology's impact on tailoring patient management with inflammation-driven risk stratification. Latest clinical results from this real-world implementation will be presented and discussed on July 19 at 7:00am at the Caristo symposium(SCCT congress venue room 512 C/F), featuring:

Caristo has achieved two significant U.S. regulatory milestones in 2025. In February, the Food and Drug Administration (FDA) granted clearance for Caristo's CaRi-Plaque™ technology for plaque and stenosis quantification. In March, the AMA CPT Panel approved a new Category III CPT® for Caristo's CaRi-Heart® technology for coronary inflammation detection and cardiovascular mortality risk assessment. SCCT attendees can book an exclusive demo of Caristo's CaRi-Heart and CaRi-Plaque technologies by clicking here to schedule the onsite demo or meeting Caristo team at Booth #304.

"We are excited to present latest clinical and research results that further validate the difference we're making in transforming health outcomes for patients," said Frank Cheng, CEO, Caristo Diagnostics.

Other sessions to watch out for at SCCT:

July 17:

AI/ ML interactive workshop (2:15-2:25pm ET | 511 A/B)

July 18:

Great Debates in Cardiac CT (1:15 PM-2:45 PM ET)

Technical advances in cardiac imaging (3:30 PM-5:00 PM ET)

About Caristo Diagnostics

Caristo Diagnostics is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo's award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention. For more information, visit caristo.com. Find Caristo online on LinkedIn, YouTube, and X.

Logo: https://mma.prnewswire.com/media/2054669/5255104/Caristo_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/caristo-to-unveil-new-clinical-and-research-results-at-scct-2025-302500066.html